Coenzyme Q10 Phase III Trial in Gulf War Illness

Completed · Phase 3 · Has a placebo group

Conditions studied: Gulf War Illness, Chronic Fatigue, Ubiquinol, Coenzyme Q10

In brief

The primary objective of this clinical trial is to determine if treatment with ubiquinol, a form of coenzyme Q10, improves the physical function of men and women Veterans suffering from Gulf War Illness (GWI). The primary outcome measure is a change from baseline on the Short Form Health Survey 36-item (SF-36), with respect to physical functioning and symptoms. Secondary outcome measures include changes from baseline levels on GWI-associated biomarkers in peripheral blood and GWI-associated symptoms of chronic pain, fatigue, insomnia, activity level, and cognitive and mental functioning.

Key facts

Study ID

NCT02865460

Run by

VA Office of Research and Development

People needed

100

Starts

2017-07-24

Expected to finish

2020-12-31

Last updated by the study team

2023-02-15

Who can join

Age: 35 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female Veterans who were deployed in 1990 -1991 Gulf War.
• Veterans who currently meet the Kansas Gulf War Study Case Definition for Gulf War Illness.
• Veterans who were in good health based on medical history prior to 1990.
• Veterans whose severity of illness is moderate to severe, evidenced by scoring less than 30 of 100 on the physical domain of SF36.

You may not qualify if…

• Veteran has a condition that may interfere with the ability to accurately report symptoms, such as:
• severe psychiatric problems
• schizophrenia
• bipolar disorder
• major depression with psychotic or melancholic features
• delusional disorders alcohol or drug dependence requiring hospitalization, or regular illegal drug use or other psychiatric condition requiring inpatient stay in the 6 months prior to study entry.
• Has dementias of any type
• Currently does not have exclusionary conditions that could reasonably be responsible for the symptoms in multi-symptom disorders, as determined by Investigator (based on Reeves et al.2003).
• Is pregnant or breastfeeding or plans to become pregnant within the next 6 months.
• Medical conditions excluded:
• organ failure
• defined rheumatologic inflammatory disorders
• chronic active infections such as HIV, hepatitis B and C, or transplant
• primary sleep disorders
• Medications that could potentially impact immune function excluded:
• steroids
• immune-suppressives
• nutraceuticals that are formulated to impact mitochondrial function or oxidative stress
• Biologic response modifiers within 3 months of study entry.
• Current use of Coumadin (given the vitamin K structural similarity of CoQ10)
• Known allergy to CoQ10 and/or inactive ingredients of active and placebo soft gelatin capsules
• Willingness to have 12 weeks of washout of current CoQ10, ubiquinol, or ubiquinone supplements will be required between the screening and baseline visits.
• Common multivitamin preparations will be allowed if taken without change throughout the protocol.

Where it is running

• Miami VA Healthcare System, Miami, FL — Miami, Florida, United States
• VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA — Boston, Massachusetts, United States
• Minneapolis VA Health Care System, Minneapolis, MN — Minneapolis, Minnesota, United States
• James J. Peters VA Medical Center, Bronx, NY — The Bronx, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.